On March 3rd, a new paper from the Memorial Sloan Kettering Cancer Center was published in Nature, entitled: "Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection".

The Targeted Locus Amplification (TLA) technology was used to sequence and map the AAV integrations.